Aadi Bioscience Inc
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa… Read more
Aadi Bioscience Inc - Asset Resilience Ratio
Aadi Bioscience Inc (AADI) has an Asset Resilience Ratio of 26.40% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Aadi Bioscience Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Aadi Bioscience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $18.57 Million | 26.4% |
| Total Liquid Assets | $18.57 Million | 26.40% |
Asset Resilience Insights
- Very High Liquidity: Aadi Bioscience Inc maintains exceptional liquid asset reserves at 26.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aadi Bioscience Inc Industry Peers by Asset Resilience Ratio
Compare Aadi Bioscience Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Aadi Bioscience Inc (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Aadi Bioscience Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 26.40% | $18.57 Million | $70.32 Million | -8.30pp |
| 2023-12-31 | 34.70% | $45.96 Million | $132.42 Million | -37.78pp |
| 2022-12-31 | 72.48% | $133.54 Million | $184.24 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $157.91 Million | -- |
| 2016-12-31 | 2.09% | $50.00K | $2.40 Million | +1.27pp |
| 2015-12-31 | 0.82% | $50.00K | $6.09 Million | -- |